Three Subsequent Single Doses of Gadolinium Chelate for Brain MR Imaging in Multiple Sclerosis

References

1. ↵
   Miller DH, Barkhof F, Albert PS, et al. Guidelines for the use of magnetic resonance techniques to monitor the treatment of multiple sclerosis. Ann Neurol 1996;39:6–16

   CrossRefPubMedWeb of Science
2. ↵
   Molyneux PD, Miller DH. Magnetic resonance imaging techniques to monitor phase III treatment trials. In: Filippi M, Grossman RI, Comi G, eds. Magnetic Resonance Techniques in Clinical Trials in Multiple Sclerosis. Milan: Springer-Verlag;1999 :49–73
3. ↵
   McFarland HF, Frank JA. The application of magnetic resonance imaging to phase II trials in multiple sclerosis. In: Filippi M, Grossman RI, Comi G, eds. Magnetic Resonance Techniques in Clinical Trials in Multiple Sclerosis. Milan: Springer-Verlag;1999 :37–48
4. ↵
   McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127

   CrossRefPubMedWeb of Science
5. ↵
   Tas MW, Barhof F, van Walderveen MAA, Polman CH, Hommes OR, Valk J. The effect of gadolinium on the sensitivity and specificity of MR imaging in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol 1995;16:259–264

   Abstract/FREE Full Text
6. ↵
   Tintore M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 2001;7:359–363

   Abstract/FREE Full Text
7. ↵
   Losseff N, Kingsley DPE, McDonald WI, et al. Clinical and magnetic resonance predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler 1996;1:218–222

   PubMed
8. ↵
   Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI disease activity in relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285–287

   Abstract/FREE Full Text
9. ↵
   Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964–969

   CrossRefPubMedWeb of Science
10. ↵
    Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994;4:141–145

    PubMed
11. ↵
    Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:540–544

    Abstract/FREE Full Text
12. Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526–530

    Abstract/FREE Full Text
13. ↵
    Filippi M, Yousry T, Campi, A, et al. Comparison of triple dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379—384

    Abstract/FREE Full Text
14. ↵
    Wolansky LJ, Finden SG, Chang R, et al. Gadoteridol in multiple sclerosis patients: a comparison of single and triple dose with immediate vs. delayed imaging. Clin Imaging 1998;22:385–392

    CrossRefPubMed
15. ↵
    Rovaris M, Rodegher M, Comi G, Filippi M. Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard- and triple-dose Gd-enhanced MRI. Eur Neurol 1999;41:123–127

    CrossRefPubMedWeb of Science
16. Rovaris M, Bastianello S, Capra R, Comi G, Yousry TA, Filippi M. Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. Magn Reson Imaging 1999;17:985–988

    CrossRefPubMedWeb of Science
17. ↵
    Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998;121:2011–2020

    Abstract/FREE Full Text
18. ↵
    Bastianello S, Gasperini C, Paolillo A, et al. Sensitivity of enhanced MR in multiple sclerosis: effects of contrast dose and magnetization transfer contrast. AJNR Am J Neuroradiol 1998;19:1863–1867

    Abstract
19. ↵
    Silver NC, Good CD, Sormani MP, et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 2001;248:215–224

    CrossRefPubMedWeb of Science
20. ↵
    Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology 1998;50:1289–1293

    Abstract/FREE Full Text
21. ↵
    Rovaris M, Mastronardo G, Prandini F, Bastianello S, Comi G, Filippi M. Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. J Neurol Sci 1999;164:148–152

    CrossRefPubMedWeb of Science
22. ↵
    Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988;15:266–272

    PubMedWeb of Science
23. ↵
    Barkhof F, Filippi M, Miller D, et al. Strategies for optimising MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244:76–84

    CrossRefPubMedWeb of Science
24. ↵
    Molyneux PD, Filippi M, Barkhof F, et al. Correlation between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332–339

    CrossRefPubMedWeb of Science
25. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant humaninterferon-B-1a: Ashort term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251–258

    Abstract/FREE Full Text
26. ↵
    Frank JA, Stone LA, Smith ME, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implication for treatment trials. Ann Neurol 1994;36(Suppl):S86–S90
27. ↵
    Gasperini C, Paolillo A, Rovaris M, Yousry TA, Capra R, Bastianello S, Filippi M. A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging 2000;18:761–763

    CrossRefPubMed
28. ↵
    Sardanelli F, Losacco C, Iozzelli A, et al. Evaluation of Gd-enhancement in brain MR of multiple sclerosis: image subtraction with and without magnetization transfer. Eur Radiol 2002;12:2077–2082

    PubMed